Covid-19 Clinical Trial
Official title:
Association Between IL-12RB and TNF-alpha Gene Polymorphism With Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study
| Verified date | July 2020 |
| Source | Assiut University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
A novel coronavirus was identified in late 2019 in Wuhan, China On 11 February, The
International Committee on Taxonomy of Viruses (ICTV) announced that the official
classification of the new coronavirus (2019-nCoV) is called severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) announced on the same day
that the official name of the disease caused by the virus is Corona Virus Disease-19
(COVID-19). WHO has declared the infection a Pandemic on March 11, 2020. Based on previous
studies on SARS in 2003 and SARS-MERS 2013 there was a genetic polymorphism associated with
the susceptibility and severity of the disease.
Interleukin-12 (IL-12) is a cytokine secreted by activated phagocytes and dendritic cells. It
plays a pivotal role in promoting Th1-type immune responses and cell-mediated immunity. IL-12
triggers many biological functions: it stimulates the proliferation of activated T- and
NK-cells, enhances T- and NK-cell-mediated cytolytic activity, and induces the production of
IFN-γ by both T-and NK-cells. The interferon-γ production induced by IL-12 forms a major link
between innate and adaptive immunity. A recent study revealed that interferon-mediated
immunopathological events are associated with atypical innate and adaptive immune responses
in SARS patients.
Also, TNF-α is a key mediator of the inflammatory response and is critical for host defense
against a wide variety of pathogenic microbes. However, the over-expression of this cytokine
may lead to badness in disease recovery. The dual role of TNF, acting as an agent of both
innate immunity and inflammatory pathology, poses a considerable challenge for gene
regulation.
| Status | Active, not recruiting |
| Enrollment | 100 |
| Est. completion date | July 30, 2020 |
| Est. primary completion date | June 18, 2020 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Patients with confirmed COVID-19 PCR ( mild, moderate and severe cases) admitted to wards or ICU Assiut University Hospitals Exclusion Criteria: - Suspected or non confirmed cases of COVID-19 |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Assiut University Hospitals | Assiut | |
| Egypt | AssiutU | Assiut |
| Lead Sponsor | Collaborator |
|---|---|
| Assiut University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measure level of polymorphisms of interleukin (IL)-12 receptor B1 (IL-12RB1) and TNF- a alpha on COVID-19 related severe acute respiratory syndrome (SARS-CoV-2). | genetic polymorphism | day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|